Publicacións (454) Publicacións nas que participase algún/ha investigador/a

2023

  1. N-adamantyl-anthranil amide derivatives: New selective ligands for the cannabinoid receptor subtype 2 (CB2R)

    European Journal of Medicinal Chemistry, Vol. 248

  2. Exploring the Effect of Halogenation in a Series of Potent and Selective A2BAdenosine Receptor Antagonists

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 890-912

  3. Development of N-(1-Adamantyl)benzamides as Novel Anti-Inflammatory Multitarget Agents Acting as Dual Modulators of the Cannabinoid CB2 Receptor and Fatty Acid Amide Hydrolase

    Journal of Medicinal Chemistry, Vol. 66, Núm. 1, pp. 235-250

  4. 8-Amide and 8-carbamate substitution patterns as modulators of 7-hydroxy-4-methylcoumarin's antidepressant profile: Synthesis, biological evaluation and docking studies

    European Journal of Medicinal Chemistry, Vol. 248

  5. 3D printing of a palladium-alumina cermet monolithic catalyst: catalytic evaluation in microwave-assisted cross-coupling reactions

    Materials Today Chemistry, Vol. 27

2022

  1. Identification of Sodium Transients Through NaV1.5 Channels as Regulators of Differentiation in Immortalized Dorsal Root Ganglia Neurons

    Frontiers in Cellular Neuroscience, Vol. 16

  2. Identification of A2BAR as a potential target in colorectal cancer using novel fluorescent GPCR ligands

    Biomedicine and Pharmacotherapy, Vol. 153

  3. From Serendipity to Rational Identification of the 5,6,7,8-Tetrahydrobenzo[4,5]thieno[2,3-d]pyrimidin-4(3H)-one Core as a New Chemotype of AKT1 Inhibitors for Acute Myeloid Leukemia

    Pharmaceutics, Vol. 14, Núm. 11

  4. Exploring Non-orthosteric Interactions with a Series of Potent and Selective A3Antagonists

    ACS Medicinal Chemistry Letters, Vol. 13, Núm. 2, pp. 243-249

  5. Discovery of V-0219: A Small-Molecule Positive Allosteric Modulator of the Glucagon-Like Peptide-1 Receptor toward Oral Treatment for "diabesity"

    Journal of Medicinal Chemistry, Vol. 65, Núm. 7, pp. 5449-5461

  6. Discovery and In Vivo Proof of Concept of a Highly Potent Dual Inhibitor of Soluble Epoxide Hydrolase and Acetylcholinesterase for the Treatment of Alzheimer's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 6, pp. 4909-4925

  7. Design, synthesis, and in vitro and in vivo characterization of new memantine analogs for Alzheimer's disease

    European Journal of Medicinal Chemistry, Vol. 236

  8. Design, Synthesis and 5-HT1A Binding Affinity of N-(3-(4-(2-Methoxyphenyl)piperazin-1-yl)propyl)tricyclo[3.3.1.13,7 ]decan-1-amine and N-(3-(4-(2-Methoxyphenyl) piperazin-1-yl)propyl)-3,5-dimethyl-tricylo[3.3.1.13,7 ]decan-1-amine

    MolBank, Vol. 2022, Núm. 1

  9. Design and Synthesis of Arylpiperazine Serotonergic/ Dopaminergic Ligands with Neuroprotective Properties

    Molecules, Vol. 27, Núm. 4

  10. Collaboration and knowledge integration for successful brain therapeutics – lessons learned from the pandemic

    DMM Disease Models and Mechanisms, Vol. 15, Núm. 12

  11. An Experience of Using a Canvas-Based Template for Blended-Learning in a Master in Drug Discovery

    International Journal of Emerging Technologies in Learning, Vol. 17, Núm. 6, pp. 257-267

  12. Allosteric modulation of dopamine D2L receptor in complex with Gi1 and Gi2 proteins: the effect of subtle structural and stereochemical ligand modifications

    Pharmacological Reports, Vol. 74, Núm. 2, pp. 406-424

  13. A New Family of Subnanomolar inhibitors of Soluble Epoxide Hydrolase

    FASEB journal : official publication of the Federation of American Societies for Experimental Biology, Vol. 36

  14. A 2B adenosine receptor antagonists rescue lymphocyte activity in adenosine-producing patient-derived cancer models

    Journal for ImmunoTherapy of Cancer, Vol. 10, Núm. 5

  15. 2-(Fluoromethoxy)-4′-(S-methanesulfonimidoyl)-1,1′-biphenyl (UCM-1306), an Orally Bioavailable Positive Allosteric Modulator of the Human Dopamine D1Receptor for Parkinson's Disease

    Journal of Medicinal Chemistry, Vol. 65, Núm. 18, pp. 12256-12272